MedTrace Logo

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT04015375 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1150

Last updated 2020-04-02

No results posted yet for this study

Summary

To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)

Topical gel

DRUG

ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)

Topical gel

OTHER

Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)

Topical gel

Sponsors & Collaborators

  • Catawba Research

    collaborator UNKNOWN

  • Torrent Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Caryn Thompson, MBA · Catawba Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-11
Primary Completion
2020-02-03
Completion
2020-02-22
FDA Drug
Yes

Countries

  • United States
  • Belize

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04015375 on ClinicalTrials.gov